Development of Siddha drug bio-artermin against viral and malarial disease - Clinical trials & formulation
Principal Investigator
Prof. Satyanarayana Gummadi
Objective
- We aim to present Arujunetin and Artemisinin combination as a Siddha product with significant potential for antiviral and antimalarial applications, catering to the global Siddha community.
Description
- Despite significant scientific progress over the past two decades, malaria continues to pose a global burden. Traditional anti-malarial remedies offer promising avenues for the discovery of new anti-plasmodial compounds, while also ensuring equitable access to care for all individuals. An estimated 25.44 lakh people are living with HIV in India in 2023. According to experts, the studies highlight the urgent need to strengthen existing prevention, diagnosis and treatment strategies and to focus efforts in the most at-risk areas to accelerate progress toward the goal of ending AIDS by 2030. Our products will help and cure the HIV patients and Malaria, dengue patients.
Impact
- We have developed a special product Bio-Artermin siddha using a patented extract from the bark of the Terminalia arjuna tree and Artemisia annua. This product is designed to help fight malaria and viral diseases, especially dengue, chikungunya, and HIV.
Budget in Lakhs
60.00